San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Good news for anyone who thought Fitbit's move toward the smartwatch market would be a move away from health: The wearable maker has just announced a partnership with Dexcom that will bring data from ...
It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...
20don MSN
DexCom reiterates $5.16B-$5.25B 2026 revenue outlook while raising operating margin to 23%-23.5%
Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter ...
DexCom boosted its 2026 non-GAAP operating margin guidance to 23%-23.5% after reporting strong Q1 revenue growth and product momentum. Management credited expanded coverage for type 2 non-insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results